The results of a study presented at the 17th International Myeloma Workshop might provide the rational for predicting multiple myeloma (MM) patient status for targeted and immune therapy.
There exists a higher rate of multiple myeloma (MM) progression in younger patients with smoldering multiple myeloma patients than old ones.
Multiple myeloma (MM) patients with a fracture at diagnosis have a higher risk of dying compared to patients without a fracture
Researchers have uncovered that both T cell-intrinsic and microenvironment factors are associated with clinical response to anti-BCMA CAR-T cells in refractory myeloma.
Clinical Responses and Pharmacokinetics of Fully Human BCMA Targeting CAR-T Cell Therapy in Relapsed/Refractory...
This early-stage clinical study, presented at the 17th International Myeloma Workshop, exhibited the safety and efficacy of CT103A in heavily pretreated R/R multiple myeloma (RRMM) patients.